# Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

> **NCT01595685** · PHASE3 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 98 (actual)

## Conditions studied

- Chronic Viral Hepatitis B Without Delta-agent

## Interventions

- **DRUG:** Telbivudine
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01595685
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01595685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01595685, "Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01595685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*